Last reviewed · How we verify
Januvia generic
About Januvia
Januvia (SITAGLIPTIN) — originally marketed by Zydus Lifesciences. Class: Dipeptidyl Peptidase 4 Inhibitor [EPC]. First approved 2006-01-01.
Approved generic versions (12)
| Generic | Manufacturer | Phase | First approval | Country |
|---|---|---|---|---|
| SITAGLIPTIN PHOSPHATE | marketed | 2006-01-01 | ||
| sitagliptin and metformin | University Medical Centre Ljubljana | marketed | ||
| Sitagliptin and Gliclazide | Zhibin Xu | marketed | ||
| sitagliptin and acarbose | Nanjing First Hospital, Nanjing Medical University | marketed | ||
| Sitagliptin combined with Beidougen capsule | Beijing Chao Yang Hospital | marketed | ||
| SITAGLIPTIN AND METFORMIN HCL | MANKIND PHARMA LTD | marketed | ||
| Sitagliptin combined with metformin | Sun Yat-sen University | marketed | ||
| Sitagliptin (Januvia) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | marketed | ||
| Sitagliptin + Metformin | Baylor College of Medicine | marketed | ||
| Sitagliptin phosphate/metformin hydrochloride FDC | Merck Sharp & Dohme LLC | marketed | ||
| Sitagliptin - DPP4i | Royal Devon and Exeter NHS Foundation Trust | marketed | ||
| Sitagliptin (Novartis, USA) | Al-Azhar University | marketed |
Originator patent timeline
Active patents (0)
Expired patents (0)
How small-molecule generic approval works
Generic versions of small-molecule drugs are approved by the FDA via the Abbreviated New Drug Application (ANDA) pathway under the Hatch-Waxman Act of 1984. Sponsors must demonstrate bioequivalence (pharmacokinetic equivalence within tight bounds) and identical chemical composition — no clinical trials in patients are required. Approval typically takes 18-24 months.
This is different from biosimilars for biologic drugs, which use the more complex 351(k) BLA pathway and typically achieve smaller (15-35%) discounts vs the originator. Small-molecule generics typically launch at 60-80% discount, dropping to 85-95% within 2 years.